4D Molecular Therapeutics FDMT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$209.18M-45.8% | -$196.14M-78.5% | -$176.44M-68.8% | ||
| $4.91M+8.4% | $4.69M+0.9% | $4.57M-1.8% | $4.5M+0.9% | $4.53M+4.2% | ||
| $19.48M-28.2% | $22.02M-15.7% | $24.04M-1.7% | $26.01M+15.5% | $27.13M+26.7% | ||
| —— | —— | —— | $5.27M— | -$67K— | ||
| $6.34M— | $8.15M— | —— | —— | —— | ||
| —— | —— | —— | $7.07M+314% | $6.27M+12,965% | ||
| $1.19M— | -$209K— | —— | —— | —— | ||
| $3.01M+29.1% | $2.93M+42.8% | $2.86M+60.8% | $2.63M+57.8% | $2.33M+47.4% | ||
| -$3.32M-74.2% | -$3.19M-93.4% | -$2.57M-34.6% | -$2.16M-9.6% | -$1.9M-26.0% | ||
| —— | —— | -$183.5M-61.9% | -$166.39M-95.4% | -$153.26M-99.1% | ||
| —— | —— | —— | $3.42M+70.1% | $3.71M+50.1% | ||
| -$56.03M— | -$92.97M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $124.44M+576% | $112.96M-66.5% | $1.58M-99.5% | $2.03M-99.4% | $18.42M-96.0% | ||
| —— | —— | -$138.98M— | -$111.9M— | -$142.07M— | ||
| $4.6M-40.2% | $4.73M-34.1% | $5.44M-6.4% | $6.52M+75.3% | $7.69M+379% | ||
| —— | —— | —— | —— | -$47K-131% | ||
| -$3.32M-74.2% | -$3.19M-93.4% | -$2.57M-34.6% | -$2.16M-9.6% | -$1.9M-26.0% | ||
| —— | —— | —— | —— | —— | ||
| $3.01M+29.1% | $2.93M+42.8% | $2.86M+60.8% | $2.63M+57.8% | $2.33M+47.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $7.5M— | $5.63M— | $3.75M— | $1.88M— | ||
| —— | $984K-78.5% | $1.88M— | $2.78M— | $3.68M— | ||
| —— | —— | —— | —— | —— | ||
| $1.19M— | -$209K— | —— | —— | —— | ||
| -$3.32M-74.2% | -$3.19M-93.4% | -$2.57M-34.6% | -$2.16M-9.6% | -$1.9M-26.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | $307K— | $230.25K— | $153.5K— | $76.75K— | ||
| —— | —— | -$185.05M-58.5% | -$169.81M-94.8% | -$156.96M-97.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does 4D Molecular Therapeutics generate?
- 4D Molecular Therapeutics (FDMT) generated -$205.8M in operating cash flow over the trailing twelve months.
- What is 4D Molecular Therapeutics's free cash flow?
- After $1.6M of capital expenditures, 4D Molecular Therapeutics's free cash flow was -$206.4M over the trailing twelve months, down 49.1% year over year.
- Where does 4D Molecular Therapeutics's cash flow data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
